Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

You may be eligible if

• Moderate to severe active ulcerative colitis diagnosed for at least 4 months.
• Mayo score of 5-10 (inclusive)
• Not used any investigational therapy for 30 days prior to screening
• No treatment with monoclonal antibody therapy within 12 weeks of screening
• No prior treatment with daclizumab